News

The IND acceptance will allow the company to begin an open label Phase I/II trial designed to evaluate its wholly-owned MAGE-A10 T therapeutic candidate in NSCLC. Currently, the

For the NDA, the FDA has provided an anticipated Prescription Drug User Fee Act (PDUFA) action date in February 2016. The NDA of Xeljanz 11mg is based on

Spiolto Respimat is now approved in Croatia, the UK, Slovakia, Denmark, Norway, Ireland, Austria, Romania and Spain. The company said that Spiolto Respimat provides significant improvements in lung

KTE-C19 is an investigational therapy in which a patient’s T cells are genetically modified to express a Chimeric Antigen Receptor (CAR) designed to target CD19, a protein expressed

Aspirin and extended-release dipyridamole capsules are used to lower the risk of stroke in people who have had a mini-stroke (transient ischemic attack or TIA) or stroke due

The collaboration brings together TES Pharma, a research-based biotech company led by Professor Roberto Pellicciari (Scientific Co-Founder of Intercept Pharmaceuticals, Inc) with state of the art research facilities

The collaboration will focus on the development of a portfolio of AGTC’s therapeutic programs, including both a clinical stage candidate and a pre-clinical candidate for orphan diseases of

Rociletinib is the Company’s novel, oral targeted covalent (irreversible) mutant-selective inhibitor of EGFR in development for the treatment of NSCLC in patients with initial activating EGFR mutations, as

Alchemia Oncology Pty Limited has a robust collection of clinical and pre-clinical oncology assets, which include the HyACT Drug Delivery Platform, a portfolio of targeted therapeutics which are